Working… Menu

Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00072449
Recruitment Status : Terminated (slow accrual and lack of resources and priority due to combining 2 consortia)
First Posted : November 6, 2003
Results First Posted : August 28, 2013
Last Update Posted : August 28, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Tracking Information
First Submitted Date  ICMJE November 4, 2003
First Posted Date  ICMJE November 6, 2003
Results First Submitted Date  ICMJE June 14, 2013
Results First Posted Date  ICMJE August 28, 2013
Last Update Posted Date August 28, 2013
Study Start Date  ICMJE May 2004
Actual Primary Completion Date March 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 14, 2013)
Radiographic Response [ Time Frame: 1 month, 2 months and then q3months ]
it at any time point patient progresses no more scans are required, patient is off study
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00072449 on Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 14, 2013)
  • Progression-free Survival [ Time Frame: pt had MRI q3months ]
    pt had MRI every 3 months
  • Overall Survival [ Time Frame: 47 months ]
    survival was evaluated q 2months
  • Toxicity [ Time Frame: 8 weeks - 2 cycles ]
    patients only received drug for 8 weeks
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
Official Title  ICMJE A Phase II Study Of Anti-CD20 Monoclonal Antibody (Rituximab) Therapy For Patients With Refractory Or Relapsed Primary CNS Lymphoma (PCNSL)
Brief Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have refractory or relapsed primary CNS lymphoma.

Detailed Description



  • Determine the radiographic response proportion in patients with refractory or recurrent primary CNS lymphoma treated with rituximab.


  • Determine the progression-free and overall survival of patients treated with this drug.
  • Determine the toxicity profile of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive rituximab IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of rituximab off study at the discretion of the treating physician.

Patients are followed every 2 months.

PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 5-9 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphoma
Intervention  ICMJE Biological: rituximab
Study Arms  ICMJE Experimental: Rituximab monotherapy
Rituximab administered at a dose of 375mg/m2 as a single IV infusion every week for up to 8 weeks
Intervention: Biological: rituximab
Publications * Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011 Mar 8;76(10):929-30. doi: 10.1212/WNL.0b013e31820f2d94.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: May 1, 2012)
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE June 2010
Actual Primary Completion Date March 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE


  • Histologically confirmed primary CNS lymphoma based on 1 of the following:

    • Histologically confirmed non-Hodgkin's B-cell lymphoma by brain biopsy or resection
    • Positive cerebrospinal fluid (CSF) cytology or immunohistochemical diagnosis of CSF monoclonality with or without measurable intracranial disease
    • Histologically confirmed vitreal lymphoma with measurable intracranial tumor
  • CD20 positive by brain biopsy
  • Measurable (greater than 1 cm in diameter) tumor by CT scan or MRI
  • Progressed during first-line chemotherapy and/or radiotherapy OR relapsed after initial successful treatment
  • No systemic lymphoma by CT scan of the chest, abdomen, and pelvis with contrast
  • No leptomeningeal lymphoma by lumbar puncture for CNS cytology/flow cytometry
  • No ocular lymphoma by slit lamp examination



  • 18 and over

Performance status

  • Karnofsky 60-100%

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL


  • Bilirubin less than 1.5 mg/dL
  • Transaminases less than 4 times upper limit of normal


  • Creatinine less than 1.5 mg/dL


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 1 year after study participation
  • HIV negative
  • Mini mental status examination score at least 15
  • No concurrent serious infection
  • No other medical illness that would preclude study treatment
  • No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ


Biologic therapy

  • More than 90 days since prior biologic therapy
  • No prior rituximab
  • No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)

Endocrine therapy

  • Not specified


  • See Disease Characteristics
  • At least 3 months since prior radiotherapy


  • Not specified


  • Recovered from prior therapy
  • More than 90 days since prior investigational drugs
  • More than 90 days since prior use of a therapeutic device
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00072449
Other Study ID Numbers  ICMJE NABTT-2201 CDR0000339737
U01CA062475 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Sponsor  ICMJE Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Study Chair: Tracy Batchelor, MD, MPH Massachusetts General Hospital
PRS Account Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Verification Date June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP